<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) with mutational activation of KRAS is observed frequently </plain></SENT>
<SENT sid="1" pm="."><plain>In addition, PIK3CA mutations commonly coexist with KRAS mutations and lead to additive activation of the PI3K/MTOR signaling pathway </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we investigated how <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells that harbor KRAS and PIK3CA mutations affect sensitivity to inhibition of PI3K/MTOR with NVP-BEZ235 (BEZ235) </plain></SENT>
<SENT sid="3" pm="."><plain>We selected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patient samples and assessed their mutational status </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with KRAS or PIK3CA mutations show activation of AKT and MTOR, particularly when KRAS and PIK3CA mutations coexist </plain></SENT>
<SENT sid="5" pm="."><plain>Suppression of PI3K/MTOR by BEZ235 results in a growth inhibitory effect and enhanced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> via BIM activation in KRAS mutant cells </plain></SENT>
<SENT sid="6" pm="."><plain>Mutational activation of KRAS when accompanied by a PIK3CA mutation converges at PI3K/MTOR pathway activation, resulting in resistance to BEZ235 </plain></SENT>
<SENT sid="7" pm="."><plain>BIM knockdown blocked the apoptotic response to BEZ235 in KRAS mutant cells, suggesting that PI3K inhibition leads to BIM accumulation </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, BEZ235 treatment resulted in induction of FOXO3A activity and its induced transcription of BIM activation, which sensitized cells to cytotoxic agents leading to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in double mutant cells in vitro and in vivo </plain></SENT>
<SENT sid="9" pm="."><plain>Taken together, our data suggest that targeting PI3K/MTOR sensitizes cells to <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, implying that activation of PI3K/MTOR signaling via KRAS or PIK3CA mutation is an important pathway in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell growth </plain></SENT>
<SENT sid="10" pm="."><plain>Based on these results, coexistent KRAS and PIK3CA mutations confer resistance to BEZ235 via suppression of BIM-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, suggesting that combined treatment with conventional chemoagents is a potential strategy in the clinic </plain></SENT>
</text></document>